نتائج البحث

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, or Everolimus in ER+, HER2- Breast Cancer

• Authors : Novartis

• Source: A Phase 1b Open-Label Multicenter Study of OP-1250 (Palazestrant) in Combination With the CDK4/6 Inhibitor Ribociclib, With the PI3K Inhibitor Alpelisib, or With the mTOR Inhibitor

تفاصيل العنوان

Conversion between sirolimus and everolimus in heart transplant recipients.

• Authors : Wert TJ; Department of Pharmacy, Vanderbilt University Medical Center, Nashville, USA.; Heeney S

Subjects: Sirolimus*/Sirolimus*/Sirolimus*/therapeutic use ; Heart Transplantation*; Adult

• Source: Clinical transplantation [Clin Transplant] 2023 Nov; Vol. 37 (11), pp. e15102. Date of Electronic Publication: 2023 Aug 17.Publisher: Munksgaard Country of Publication: Denmark NLM ID: 8710240 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1399-0012

تفاصيل العنوان

Effects of a ritonavir-containing regimen on the pharmacokinetics of sirolimus or everolimus in healthy adult subjects.

• Authors : Zha J; AbbVie Inc. (Clinical Pharmacology), North Chicago, Illinois, USA.; Jiang Q

Subjects: Everolimus*/Everolimus*/Everolimus*/pharmacokinetics ; Ritonavir*/Ritonavir*/Ritonavir*/pharmacology ; Sirolimus*/Sirolimus*/Sirolimus*/pharmacokinetics

• Source: Pharmacology research & perspectives [Pharmacol Res Perspect] 2022 Dec; Vol. 10 (6), pp. e01024.Publisher: John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States

تفاصيل العنوان

Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer

• Source: A Phase I Trial of Sirolimus or Everolimus or Temsirolimus (mTOR Inhibitor) and Vorinostat (Histone Deacetylase Inhibitor) in Patients

تفاصيل العنوان

Assessment of the adverse effects of sirolimus versus everolimus in pediatric heart transplant recipients.

• Authors : Newland DM; Department of Pharmacy, Seattle Children's Hospital, Seattle, Washington, USA.; School of Pharmacy, University of Washington, Seattle, Washington, USA.

Subjects: Sirolimus*/Sirolimus*/Sirolimus*/adverse effects ; Heart Transplantation*; Humans

• Source: Pediatric transplantation [Pediatr Transplant] 2023 May; Vol. 27 (3), pp. e14487. Date of Electronic Publication: 2023 Mar 03.Publisher: Munksgaard Country of Publication: Denmark NLM ID: 9802574 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1399-3046

تفاصيل العنوان

Investigation of the effects of mTOR inhibitors rapamycin and everolimus in combination with carboplatin on canine malignant melanoma cells.

• Authors : Bernard S; Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.; Poon AC

Subjects: Carboplatin*/Carboplatin*/Carboplatin*/pharmacology ; Carboplatin*/Carboplatin*/Carboplatin*/therapeutic use ; Dog Diseases*/Dog Diseases*/Dog Diseases*/drug therapy

• Source: BMC veterinary research [BMC Vet Res] 2021 Dec 11; Vol. 17 (1), pp. 382. Date of Electronic Publication: 2021 Dec 11.Publisher: BioMed Central Country of Publication: England NLM ID: 101249759 Publication Model: Electronic Cited Medium: Internet ISSN: 1746-6148

تفاصيل العنوان

Immunosuppressive Effects and Potent Anti-tumor Efficacy of mTOR Inhibitor Everolimus in Breast Tumor-bearing Mice.

• Authors : Rostamzadeh D; Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran AND Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. .; Haghshenas MR

Subjects: Breast Neoplasms*/Breast Neoplasms*/Breast Neoplasms*/drug therapy ; Sirolimus*/Sirolimus*/Sirolimus*/pharmacology ; Sirolimus*/Sirolimus*/Sirolimus*/therapeutic use

• Source: Iranian journal of allergy, asthma, and immunology [Iran J Allergy Asthma Immunol] 2022 Jun 18; Vol. 21 (3), pp. 287-299. Date of Electronic Publication: 2022 Jun 18.Publisher: Tehran University of Medical Sciences Country of Publication: Iran NLM ID: 101146178 Publication Model: Electronic Cited Medium: Internet

تفاصيل العنوان

Comparative Vascular Effects of Sirolimus and Everolimus on Isolated Human Saphenous Veins.

• Authors : Kaleli Durman, Deniz¹ (AUTHOR) ; Civelek, Erkan^1,2 (AUTHOR); Alp Yildirim, Fatoş İlkay¹ (AUTHOR)

• Source: Life (2075-1729). Apr2025, Vol. 15 Issue 4, p553. 11p.

تفاصيل العنوان

A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients.

• Authors : Ouyang H; Department of Clinical Laboratory, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, 1 Fuhua Road, Shenzhen, Guangdong, 518033, People's Republic of China.; Zeng X

Subjects: Drug-Eluting Stents*; Cardiovascular Agents/Cardiovascular Agents/Cardiovascular Agents/*administration & dosage ; Diabetic Angiopathies/Diabetic Angiopathies/Diabetic Angiopathies/*therapy

• Source: Journal of cardiothoracic surgery [J Cardiothorac Surg] 2021 Apr 17; Vol. 16 (1), pp. 90. Date of Electronic Publication: 2021 Apr 17.Publisher: BioMed Central Country of Publication: England NLM ID: 101265113 Publication Model: Electronic Cited Medium: Internet ISSN: 1749-8090

تفاصيل العنوان

Tremor Induced by Cyclosporine, Tacrolimus, Sirolimus, or Everolimus: A Review of the Literature

• Authors : Aparna Wagle Shukla; Caroline Lunny; Omar Mahboob

Subjects: Sirolimus; Calcineurin Inhibitors; RM1-950

• Source: Drugs R DDrugs in R&D, Vol 23, Iss 4, Pp 301-329 (2023)

تفاصيل العنوان